Hormone receptor status, erbB2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients

Histology and Histopathology

Volumn 27, Issue 7, 2012, Pages 855-864

  Rack, Brigitte ^a   Bock, Carolin ^a   Andergassen, Ulrich ^a   Doisneau Sixou, Sophie ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Breast cancer; Cancer stem cells; Circulating tumor cells; ErbB2; Estrogen receptor alpha

Indexed keywords

EID: 84861873500     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M. and Brauch H. (2005). Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11, 1154-1159.
2. Aitken S.J., Thomas J.S., Langdon S.P., Harrison D.J. and Faratian D. (2010). Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann. Oncol. 21, 1254-1261.
3. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R. and Kasimir-Bauer S. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11, R46.
4. Aktas B., Muller V., Tewes M., Zeitz J., Kasimir-Bauer S., Loehberg C.R., Rack B., Schneeweiss A. and Fehm T. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol. Oncol. 122, 356-360.
5. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J. and Clarke M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
6. Arslan C., Sari E., Aksoy S. and Altundag K. (2011). Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin. Ther. Targets 15, 21-30.
7. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., Datar R.H. and Cote R.J. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621.
8. Bonnomet A., Brysse A., Tachsidis A., Waltham M., Thompson E.W., Polette M. and Gilles C. (2010). Epithelial-to-mesenchymal transitions and circulating tumor cells. J. Mammary Gland Biol. Neoplasia 15, 261-273.
9. Braun S., Pantel K., Muller P., Janni W., Hepp F., Kentenich C.R., Gastroph S., Wischnik A., Dimpfl T., Kindermann G., Riethmuller G. and Schlimok G. (2000). Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl. J. Med. 342, 525-533.
10. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., Matera J., Repollet M., Doyle G.V., Terstappen L.W. and Hayes D.F. (2006). Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12, 6403-6409.
11. Chambers A.F., Naumov G.N., Vantyghem S.A. and Tuck A.B. (2000). Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2, 400-407.
12. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., Hur M.H., Diebel M.E., Monville F., Dutcher J., Brown M., Viens P., Xerri L., Bertucci F., Stassi G., Dontu G., Birnbaum D. and Wicha M.S. (2009). Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69, 1302-1313.
13. Cheng L., Alexander R., Zhang S., Pan C.X., Maclennan G.T., Lopez-Beltran A. and Montironi R. (2011). The clinical and therapeutic implications of cancer stem cell biology. Expert Rev. Anticancer Ther. 11, 1133-1145.
14. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W. and Meropol N.J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213-3221.
15. Collins A.T., Berry P.A., Hyde C., Stower M.J. and Maitland N.J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951.
16. Cote R.J., Rosen P.P., Lesser M.L., Old L.J. and Osborne M.P. (1991). Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9, 1749-1756.
17. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M. and Chang J.C. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 106, 13820-13825.
18. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W. and Hayes D.F. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl. J. Med. 351, 781-791.
19. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., Fritsche H.A., Hortobagyi G.N. and Terstappen L.W. (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23, 1420-1430.
20. Dalenc F., Doisneau-Sixou S.F., Allal B.C., Marsili S., Lauwers-Cances V., Chaoui K., Schiltz O., Monsarrat B., Filleron T., Renee N., Malissein E., Meunier E., Favre G. and Roche H. (2010). Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin. Cancer Res. 16, 1264-1271.
21. Daskalaki A., Agelaki S., Perraki M., Apostolaki S., Xenidis N., Stathopoulos E., Kontopodis E., Hatzidaki D., Mavroudis D. and Georgoulias V. (2009). Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br. J. Cancer 101, 589-597.
22. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., Doyle G.V., Terstappen L.W., Pienta K.J. and Raghavan D. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309.
23. De Giorgi U., Valero V., Rohren E., Dawood S., Ueno N.T., Miller M.C., Doyle G.V., Jackson S., Andreopoulou E., Handy B.C., Reuben J.M., Fritsche H.A., Macapinlac H.A., Hortobagyi G.N. and Cristofanilli M. (2009). Circulating tumor cells and [18F]fluoro-deoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J. Clin. Oncol. 27, 3303-3311.
24. De Vita V.T. Jr (1989). Breast cancer therapy: exercising all our options. N. Engl. J. Med. 320, 527-529.
25. Di Cosimo S. and Baselga J. (2008). Targeted therapies in breast cancer: where are we now? Eur. J. Cancer 44, 2781-2790.
26. Di Cosimo S. and Baselga J. (2010). Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat. Rev. Clin. Oncol. 7, 139-147.
27. Diel I.J., Kaufmann M., Costa S.D., Holle R., von Minckwitz G., Solomayer E.F., Kaul S. and Bastert G. (1996). Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 88, 1652-1658.
28. Fehm T., Krawczyk N., Solomayer E.F., Becker-Pergola G., Durr-Storzer S., Neubauer H., Seeger H., Staebler A., Wallwiener D. and Becker S. (2008). ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 10, R76.
29. Fehm T., Hoffmann O., Aktas B., Becker S., Solomayer E.F., Wallwiener D., Kimmig R. and Kasimir-Bauer S. (2009). Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 11, R59.
30. Fehm T., Muller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Lohberg C.R., Solomayer E., Rack B., Riethdorf S., Klein C., Schindlbeck C., Brocker K., Kasimir-Bauer S., Wallwiener D. and Pantel K. (2010). HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 124, 403-412.
31. Fulford L.G., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., Hanby A., Easton D. and Lakhani S.R. (2007). Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 9, R4.
32. Gebauer G., Fehm T., Merkle E., Beck E.P., Lang N. and Jager W. (2001). Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J. Clin. Oncol. 19, 3669-3674.
33. Gerber B., Krause A., Muller H., Richter D., Reimer T., Makovitzky J., Herrnring C., Jeschke U., Kundt G. and Friese K. (2001). Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J. Clin. Oncol. 19, 960-971.
34. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S. and Dontu G. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567.
35. Giordano A., Giuliano M., De Laurentiis M., Arpino G., Jackson S., Handy B.C., Ueno N.T., Andreopoulou E., Alvarez R.H., Valero V., De Placido S., Hortobagyi G.N., Reuben J.M. and Cristofanilli M. (2012). Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann. Oncol. 23, 1144-1150.
36. Giuliano M., Giordano A., Jackson S., Hess K.R., De Giorgi U., Mego M., Handy B.C., Ueno N.T., Alvarez R.H., De Laurentiis M., De Placido S., Valero V., Hortobagyi G.N., Reuben J.M. and Cristofanilli M. (2011). Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 13, R67.
37. Gomez-Fernandez C., Daneshbod Y., Nassiri M., Milikowski C., Alvarez C. and Nadji M. (2008). Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am. J. Clin. Pathol. 130, 879-882.
38. Gong Y., Symmans W.F., Krishnamurthy S., Patel S. and Sneige N. (2004). Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Cancer 102, 34-40.
39. Harbeck N., Untch M., Pache L. and Eiermann W. (1994). Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br. J. Cancer 69, 566-571.
40. Hayashi N., Nakamura S., Tokuda Y., Shimoda Y., Yagata H., Yoshida A., Ota H., Hortobagyi G.N., Cristofanilli M. and Ueno N.T. (2011). Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int. J. Clin. Oncol.
41. Hayes D.F. and Smerage J.B. (2010). Circulating tumor cells. Prog. Mol. Biol. Transl. Sci. 95, 95-112.
42. Honeth G., Bendahl P.O., Ringner M., Saal L.H., Gruvberger-Saal S.K., Lovgren K., Grabau D., Ferno M., Borg A. and Hegardt C. (2008). The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10, R53.
43. Hwang-Verslues W.W., Kuo W.H., Chang P.H., Pan C.C., Wang H.H., Tsai S.T., Jeng Y.M., Shew J.Y., Kung J.T., Chen C.H., Lee E.Y., Chang K.J. and Lee W.H. (2009). Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4, e8377.
44. Iinuma H., Watanabe T., Mimori K., Adachi M., Hayashi N., Tamura J., Matsuda K., Fukushima R., Okinaga K., Sasako M. and Mori M. (2011). Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 29, 1547-1555.
45. Kaiser J. (2010). Medicine. Cancer's circulation problem. Science 327, 1072-1074.
46. Kantelhardt E.J., Vetter M., Schmidt M., Veyret C., Augustin D., Hanf V., Meisner C., Paepke D., Schmitt M., Sweep F., von Minckwitz G., Martin P.M., Jaenicke F., Thomssen C. and Harbeck N. (2011).Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer 11, 140.
47. Konecny G., Pauletti G., Pegram M., Untch M., Dandekar S., Aguilar Z., Wilson C., Rong H.M., Bauerfeind I., Felber M., Wang H.J., Beryt M., Seshadri R., Hepp H. and Slamon D.J. (2003). Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl. Cancer Inst. 95, 142-153.
48. Kostler W.J., Brodowicz T., Hejna M., Wiltschke C. and Zielinski C.C. (2000). Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences. Cancer Detect. Prev. 24, 376-403.
49. Krishnamurthy S., Cristofanilli M., Singh B., Reuben J., Gao H., Cohen E.N., Andreopoulou E., Hall C.S., Lodhi A., Jackson S. and Lucci A. (2010). Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer 116, 3330-3337.
50. Landys K., Persson S., Kovarik J., Hultborn R. and Holmberg E. (1998). Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up. Breast Cancer Res. Treat. 49, 27-33.
51. Lee M.S., Chang K.S., Cabanillas F., Freireich E.J., Trujillo J.M. and Stass S.A. (1987). Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237, 175-178.
52. Levi F., Bosetti C., Lucchini F., Negri E. and La Vecchia C. (2005). Monitoring the decrease in breast cancer mortality in Europe. Eur. J. Cancer Prev. 14, 497-502.
53. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J. and Chang J.C. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672-679.
54. Liedtke C., Broglio K., Moulder S., Hsu L., Kau S.W., Symmans W.F., Albarracin C., Meric-Bernstam F., Woodward W., Theriault R.L., Kiesel L., Hortobagyi G.N., Pusztai L. and Gonzalez-Angulo A.M. (2009). Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann. Oncol. 20, 1953-1958.
55. Lin S.X., Chen J., Mazumdar M., Poirier D., Wang C., Azzi A. and Zhou M. (2010). Molecular therapy of breast cancer: progress and future directions. Nat. Rev. Endocrinol. 6, 485-493.
56. Liu M.C., Shields P.G., Warren R.D., Cohen P., Wilkinson M., Ottaviano Y.L., Rao S.B., Eng-Wong J., Seillier-Moiseiwitsch F., Noone A.M. and Isaacs C. (2009). Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27, 5153-5159.
57. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K. and Clarke M.F. (2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226.
58. Lower E.E., Glass E.L., Bradley D.A., Blau R. and Heffelfinger S. (2005). Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res. Treat. 90, 65-70.
59. Mansi J.L., Gogas H., Bliss J.M., Gazet J.C., Berger U. and Coombes R.C. (1999). Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354, 197-202.
60. Maynadier M., Nirde P., Ramirez J.M., Cathiard A.M., Platet N., Chambon M. and Garcia M. (2008). Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells. Adv. Exp. Med. Biol. 617, 485-491.
61. McCulloch P., Choy A. and Martin L. (1995). Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346, 1334-1335.
62. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., Beitsch P., Khan A., Euhus D., Osborne C., Frenkel E., Hoover S., Leitch M., Clifford E., Vitetta E., Morrison L., Herlyn D., Terstappen L.W., Fleming T., Fehm T., Tucker T., Lane N., Wang J. and Uhr J. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA 101, 9393-9398.
63. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., Bray R.A., Waller E.K. and Buck D.W. (1997). A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013-5021.
64. Molloy T.J., Devriese L.A., Helgason H.H., Bosma A.J., Hauptmann M., Voest E.E., Schellens J.H. and van't Veer L.J. (2011). A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br. J. Cancer 104, 1913-1919.
65. Muller V. and Pantel K. (2009). HER2 as marker for the detection of circulating tumor cells. Breast Cancer Res. Treat. 117, 535-537.
66. Negrin R.S. and Blume K.G. (1991). The use of the polymerase chain reaction for the detection of minimal residual malignant disease. Blood 78, 255-258.
67. Pachmann K., Dengler R., Lobodasch K., Frohlich F., Kroll T., Rengsberger M., Schubert R. and Pachmann U. (2008). An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. J. Cancer Res. Clin. Oncol. 134, 59-65.
68. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J. and Wolmark N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826.
69. Pantel K., Cote R.J. and Fodstad O. (1999). Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91, 1113-1124.
70. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O. and Botstein D. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
71. Pierga J.Y., Bidard F.C., Mathiot C., Brain E., Delaloge S., Giachetti S., de Cremoux P., Salmon R., Vincent-Salomon A. and Marty M. (2008). Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin. Cancer Res. 14, 7004-7010.
72. Polyak K. (2007). Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev. 3, 107-109.
73. Rack B., Schindlbeck C., Andergassen U., Lorenz R., Zwingers T., Schneeweiss A., Lichtenegger W., Beckmann M., Sommer H., Pantel K., Sommer H., Friese K. and Janni W. (2010). Prognostic role of circulating tumor cells in the peripheral blood of breast cancer patients. Cancer Res. (AACR Meeting abstracts Dec 8-12) 70, 93.
74. Rack B., Schindlbeck C., Schneeweiss A., Hilfrich J., Lorenz R., Beckmann M., Pantel K., Lichtenegger W., Sommer H. and Janni W. (2008). Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: The German SUCCESS-Trial J. Clin. Oncol. (ASCO Meeting abstracts Aug 18) 26, 503.
75. Raemaekers J.M., Beex L.V., Koenders A.J., Pieters G.F., Smals A.G., Benraad T.J. and Kloppenborg P.W. (1984). Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur. J. Cancer Clin. Oncol. 20, 1011-1018.
76. Riethdorf S., Fritsche H., Muller V., Rau T., Schindlbeck C., Rack B., Janni W., Coith C., Beck K., Janicke F., Jackson S., Gornet T., Cristofanilli M. and Pantel K. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13, 920-928.
77. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., Roller M., Huober J., Fehm T., Schrader I., Hilfrich J., Holms F., Tesch H., Eidtmann H., Untch M., von Minckwitz G. and Pantel K. (2010). Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16, 2634-2645.
78. Ring A.E., Zabaglo L., Ormerod M.G., Smith I.E. and Dowsett M. (2005). Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br. J. Cancer 92, 906-912.
79. Rodenhiser D.I., Andrews J.D., Vandenberg T.A. and Chambers A.F. (2011). Gene signatures of breast cancer progression and metastasis. Breast Cancer Res. 13, 201.
80. Rosner D. and Lane W.W. (1993). Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Res. Treat. 25, 127-139.
81. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S. and Polyak K. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273.
82. Sieuwerts A.M., Kraan J., Bolt J., van der Spoel P., Elstrodt F., Schutte M., Martens J.W., Gratama J.W., Sleijfer S. and Foekens J.A. (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J. Natl. Cancer Inst.101, 61-66.
83. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D. and Dirks P.B. (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
84. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A. and Press M.F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
85. Somlo G., Lau S.K., Frankel P., Hsieh H.B., Liu X., Yang L., Krivacic R. and Bruce R.H. (2011). Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 128, 155-163.
86. Swaby R.F. and Cristofanilli M. (2011). Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med. 9, 43.
87. Tanner M., Jarvinen P. and Isola J. (2001). Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 61, 5345-5348.
88. Tao M., Ma D., Li Y., Zhou C., Zhang Y., Duan W., Xu X., Wang R., Wu L. and Liu H. (2011). Clinical significance of circulating tumor cells in breast cancer patients. Breast Cancer Res. Treat. 129, 247-254.
89. Tewes M., Aktas B., Welt A., Mueller S., Hauch S., Kimmig R. and Kasimir-Bauer S. (2009). Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 115, 581-590.
90. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H. and Bernards R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009.
91. Van der Auwera I., Peeters D., Benoy I.H., Elst H.J., Van Laere S.J., Prove A., Maes H., Huget P., van Dam P., Vermeulen P.B. and Dirix L.Y. (2010). Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br. J. Cancer 102, 276-284.
92. Vercauteren S.M. and Sutherland H.J. (2001). CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 3, 449-459.
93. Vincent-Salomon A., Pierga J.Y., Couturier J., d'Enghien C.D., Nos C., Sigal-Zafrani B., Lae M., Freneaux P., Dieras V., Thiery J.P. and Sastre-Garau X. (2007). HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br. J. Cancer 96, 654-659.
94. Visvader J.E. (2009). Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 23, 2563-2577.
95. Visvader J.E. and Lindeman G.J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768.
96. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D. and Foekens J.A. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679.
97. Wicha M.S. and Hayes D.F. (2011). Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29, 1508-1511.
98. Woodward W.A. and Sulman E.P. (2008). Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev. 27, 459-470.
99. Wright M.H., Calcagno A.M., Salcido C.D., Carlson M.D., Ambudkar S.V. and Varticovski L. (2008). Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 10, R10.
100. Xenidis N., Ignatiadis M., Apostolaki S., Perraki M., Kalbakis K., Agelaki S., Stathopoulos E.N., Chlouverakis G., Lianidou E., Kakolyris S., Georgoulias V. and Mavroudis D. (2009). Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27, 2177-2184.
101. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S. and Gu J. (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 120, 1444-1450.
102. Zhao P., Lu Y., Jiang X. and Li X. (2011). Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 102, 1107-1111.